tradingkey.logo
tradingkey.logo
検索

Theriva Biologics Inc

TOVX
ウォッチリストに追加
0.144USD
-0.016-10.00%
終値 11-13 16:00(ET)
6.61M時価総額
損失額直近12ヶ月PER
時間外取引 19:54 (ET)0.145USD+0.002+1.40%

Theriva Biologics Incについて 企業名

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. The Company is advancing a new oncolytic adenovirus platform. The Company’s candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01, an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade the tumor stroma barrier that serves as a physical and immunosuppressive barrier to cancer treatment; SYN-004 (ribaxamase) which is designed to degrade certain commonly used IV beta-lactam antibiotics within the gastrointestinal (GI) tract to prevent microbiome damage, thereby limiting overgrowth of pathogenic organisms such as VRE (vancomycin resistant Enterococci), and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) produced under cGMP conditions and intended to treat both local GI and systemic diseases.

Theriva Biologics Inc プロフィール

企業コードTOVX
会社名Theriva Biologics Inc
上場日Feb 12, 1993
最高経営責任者「CEO」Shallcross (Steven A)
従業員数22
証券種類Ordinary Share
決算期末Feb 12
本社所在地9605 Medical Center Drive, Suite 270
都市ROCKVILLE
証券取引所NASDAQ OMX – NASDAQ Basic Amex
国United States of America
郵便番号20850
電話番号17343327800
ウェブサイトhttps://therivabio.com/
企業コードTOVX
上場日Feb 12, 1993
最高経営責任者「CEO」Shallcross (Steven A)

Theriva Biologics Incの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
Mr. Chris Calabrese
Mr. Chris Calabrese
Investor Relations
Investor Relations
--
--
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Steven A. (Steve) Shallcross
Mr. Steven A. (Steve) Shallcross
Chief Executive Officer, Chief Financial Officer and Director
Chief Executive Officer, Chief Financial Officer and Director
47.52K
+78.96%
Mr. Jeffrey J. (Jeff) Kraws
Mr. Jeffrey J. (Jeff) Kraws
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Mr. Jeffrey Alan (Jeff) Wolf, J.D.
Independent Director
Independent Director
--
--
Dr. John Monahan, Ph.D.
Dr. John Monahan, Ph.D.
Independent Director
Independent Director
--
--

よくある質問

Theriva Biologics Incの上位5名の株主は誰ですか?

Theriva Biologics Incの上位5名の株主は以下のとおりです。Mr. Steven A. (Steve) Shallcross

Theriva Biologics Inc(TOVX)の株式を保有している機関の数はいくつですか?

2026Q1時点で、Theriva Biologics Incの株式を保有している機関は51社あり、保有株式の総市場価値は約1.78Mで、全体の3.88%を占めています。2025Q4と比較して、機関の持ち株は332025.00増加しています。
tradingkey.logo
リスク告知:当社ウェブサイト及びモバイルアプリは特定の投資商品に関する一般的な情報のみを提供しており、Finsightsは金融アドバイスや投資商品の推奨を行うものではありません。本情報の提供をもってFinsightsが投資助言を行っていると解釈されることはありません。
投資商品には元本割れを含む重大なリスクが伴い、全ての投資家に適するものではありません。なお、過去の運用実績は将来の成果を保証するものではありません。
Finsightsは、第三者広告主または提携先が当社ウェブサイト・モバイルアプリ上に広告を掲載することを許可する場合があり、これら広告主から広告への反応に基づく報酬を受けることがあります。
© 著作権: FINSIGHTS MEDIA PTE. LTD. 無断複写・転載を禁じます。